Nivolumab plus ipilimumab in the treatment of advanced melanoma

Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in several novel approaches that have changed front-line management of advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Katy K., Daud, Adil I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628394/
https://www.ncbi.nlm.nih.gov/pubmed/26518223
http://dx.doi.org/10.1186/s13045-015-0219-0
_version_ 1782398446625357824
author Tsai, Katy K.
Daud, Adil I.
author_facet Tsai, Katy K.
Daud, Adil I.
author_sort Tsai, Katy K.
collection PubMed
description Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in several novel approaches that have changed front-line management of advanced melanoma. Despite these exciting developments, there remains room for improvement in treatment outcomes. Combination immunotherapy, in particular combined cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) blockade, represents an important first step in this direction.
format Online
Article
Text
id pubmed-4628394
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46283942015-11-01 Nivolumab plus ipilimumab in the treatment of advanced melanoma Tsai, Katy K. Daud, Adil I. J Hematol Oncol Commentary Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in several novel approaches that have changed front-line management of advanced melanoma. Despite these exciting developments, there remains room for improvement in treatment outcomes. Combination immunotherapy, in particular combined cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) blockade, represents an important first step in this direction. BioMed Central 2015-10-31 /pmc/articles/PMC4628394/ /pubmed/26518223 http://dx.doi.org/10.1186/s13045-015-0219-0 Text en © Tsai and Daud. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Tsai, Katy K.
Daud, Adil I.
Nivolumab plus ipilimumab in the treatment of advanced melanoma
title Nivolumab plus ipilimumab in the treatment of advanced melanoma
title_full Nivolumab plus ipilimumab in the treatment of advanced melanoma
title_fullStr Nivolumab plus ipilimumab in the treatment of advanced melanoma
title_full_unstemmed Nivolumab plus ipilimumab in the treatment of advanced melanoma
title_short Nivolumab plus ipilimumab in the treatment of advanced melanoma
title_sort nivolumab plus ipilimumab in the treatment of advanced melanoma
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628394/
https://www.ncbi.nlm.nih.gov/pubmed/26518223
http://dx.doi.org/10.1186/s13045-015-0219-0
work_keys_str_mv AT tsaikatyk nivolumabplusipilimumabinthetreatmentofadvancedmelanoma
AT daudadili nivolumabplusipilimumabinthetreatmentofadvancedmelanoma

Ejemplares similares